drugset / Trial / NCT01504906

Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor

NCT01504906

Phase 1 Completed 20 enrolled AstraZeneca
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to assess the effect of Cyclosporine on the blood levels of Ticagrelor.

Timeline

Start
2012-01
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 600 mg Oral
Subject Ticagrelor Small molecule 180 mg Oral

Indications

No indication recorded.